Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Cell>Point submits IND application for Phase 1b/2 99mTc-EC-G diagnostic trial in assessing CAD patients

Cell>Point announced today that it has submitted to the Food and Drug Administration an Investigational New Drug (IND) application for a Phase 1b/2 trial of its 99mTc-EC-G diagnostic in assessing patients with Coronary Artery Disease (CAD).

23 Jun 2010

Beneficial effects of LifeVantage's Protandim on DMD mouse model published in Journal of Dietary Supplements

LifeVantage Corporation, the maker of Protandim®, a patented, science-based solution to oxidative stress, announced today that a peer-reviewed manuscript was published in the Journal of Dietary Supplements examining the beneficial effects of Protandim® on a mouse model of Duchenne Muscular Dystrophy (DMD), an X-linked inherited disease affecting one in 3,500 males.

22 Jun 2010

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

Regulus Therapeutics Inc. and sanofi-aventis announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years.

22 Jun 2010

SYMPLICITY HTN-1 study: RDN treatment significantly reduces blood pressure

Long-term data presented today from Ardian's SYMPLICITY HTN-1 study demonstrate that the significant reductions in blood pressure achieved using Renal Denervation treatment are sustained through 24 months. The data were presented at the late breaking trials session of the European Society of Hypertension Annual Scientific meeting in Oslo, Norway.

22 Jun 2010

Elevation of Smurf1 may play a role in molecular basis of PAH: Study

Pulmonary arterial hypertension (PAH) is a progressive disease, marked by shortness of breath and fatigue which can be fatal if untreated. Increased pressure in the pulmonary artery and its branches is associated with dysfunctional growth control of endothelial and smooth muscle cells leading to excessive thickening of the blood vessel wall, obliteration of the lumen and right heart failure.

22 Jun 2010

Four-year clinical study results show sustained effect that Rheos System has on reducing hypertension

CVRx, Inc. announced today the four-year Rheos clinical results from the European study evaluating the Rheos System at the European Society of Hypertension 20th Meeting. The system is the first device designed to treat hypertension (high blood pressure), a leading cause of heart and kidney disease, stroke and death. This device is a future treatment option for the millions of people who cannot control their blood pressure with medications.

22 Jun 2010

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Affymax, Inc. and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced preliminary top-line results from the Phase 3 clinical program for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients.

21 Jun 2010

Hospitals work to reduce wait times, readmission rates

The Baltimore Sun writes about hospitals working to reduce emergency room wait times and then advertising the results. "St. Joseph Medical Center [in Towson, Md.] posts the anticipated wait time on its website. Harbor Hospital in South Baltimore has put up billboards and handed out brochures door-to-door to tell residents about its 'quick' emergency room experience.

19 Jun 2010

Women receive greater clinical benefit from CRT-Ds than men: Study

Boston Scientific Corporation today announced results from a sub-analysis of the MADIT-CRT trial data that showed women received a greater clinical benefit from its cardiac resynchronization therapy defibrillators (CRT-Ds) than men. The results were presented during the 17th Cardiostim World Congress by Jonathan Steinberg, M.D., Chief of Cardiology and Director of the Al-Sabah Arrythmia Institute, St. Luke's-Roosevelt Hospital Center, New York.

18 Jun 2010

Yearlong collaborative partnership launched to reduce hospital readmissions due to heart failure

More than 5 million individuals in the United States suffer from chronic heart failure, making it one of the most common reasons for hospitalizations and readmissions. To address this costly issue, the New Jersey Hospital Association's Institute for Quality and Patient Safety this week launched a yearlong collaborative partnership to reduce hospital readmissions due to heart failure and improve the quality of healthcare in New Jersey.

18 Jun 2010

CLEAR study meets primary endpoint: Sorin Group

Sorin Group, a global leader in the treatment of cardiovascular diseases, announced today that the CLEAR study has met its primary endpoint.

18 Jun 2010

St. Jude Medical commences enrollment in LAPTOP-HF study

St. Jude Medical, Inc., a global medical device company, today announced the first enrollment in its LAPTOP-HF (Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy) study. The goal of the LAPTOP-HF study is to demonstrate that the new investigational left atrial pressure (LAP) management system safely and effectively improves outcomes in patients with heart failure (HF).

17 Jun 2010

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

A research team from McGill University (Canada) report a beneficial effect on cardiac function in mouse models when implanted monocytes - a type of white blood cell that is part of the immune system - helped preserve cardiac function following a heart attack (myocardial infarction).

17 Jun 2010

Relypsa commences enrollment for RLY5016 Phase 2 study in heart failure patients with chronic kidney disease

Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.

16 Jun 2010

BIOTRONIK announces 10th anniversary of world's first wireless, mobile patient monitoring technology

BIOTRONIK SE & Co KG, the pioneer in wireless remote monitoring technology for patients with cardiac devices, today announced the tenth anniversary of BIOTRONIK Home Monitoring®—the world's first wireless, mobile patient monitoring technology—to be celebrated during Cardiostim in Nice, France.

16 Jun 2010

New public service advertisements to spread preventive medical testing awareness

Men are 24 percent less likely than women to have visited the doctor within the past year, according to new data released today by the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality. In addition, men are about 30 percent more likely than women to be hospitalized for preventable conditions such as congestive heart failure and complications from diabetes, according to new AHRQ data.

16 Jun 2010

ARBs may be linked with increased risk of developing cancer: US scientists

A common class of blood pressure drugs called angiotensin-receptor blockers may be linked with a slightly increased risk of developing cancer, US scientists have found.

16 Jun 2010

BIOTRONIK announces commercial availability of new ProMRI Pacing Systems

BIOTRONIK SE & Co. KG, a leading manufacturer of high-quality implantable cardiac devices and pioneer of wireless remote monitoring technologies, announced today the commercial availability of its new ProMRI Pacing Systems — Evia pacemaker series and Safio pacing leads — providing European patients the first portfolio of bradycardia systems that are compatible with Magnetic Resonance Imaging scans under specific conditions.

15 Jun 2010

Mechanical heart pumps can improve survival among patients with life-threatening heart failure: Thesis

Heart failure is a very common condition: around 200,000 people in Sweden have been diagnosed with the disease. Some patients with life-threatening heart failure can be helped by mechanical heart pumps, reveals a thesis from the University of Gothenburg, Sweden.

15 Jun 2010

FDA grants HeartWare approval for IDE destination therapy study of Ventricular Assist System

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted HeartWare conditional approval to begin enrollment in an Investigational Device Exemption (IDE) destination therapy clinical study for the HeartWare® Ventricular Assist System.

15 Jun 2010

Heart Failure News and Research

Further Reading

Cell>Point submits IND application for Phase 1b/2 99mTc-EC-G diagnostic trial in assessing CAD patients

Beneficial effects of LifeVantage's Protandim on DMD mouse model published in Journal of Dietary Supplements

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

SYMPLICITY HTN-1 study: RDN treatment significantly reduces blood pressure

Elevation of Smurf1 may play a role in molecular basis of PAH: Study

Four-year clinical study results show sustained effect that Rheos System has on reducing hypertension

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Hospitals work to reduce wait times, readmission rates

Women receive greater clinical benefit from CRT-Ds than men: Study

Yearlong collaborative partnership launched to reduce hospital readmissions due to heart failure

CLEAR study meets primary endpoint: Sorin Group

St. Jude Medical commences enrollment in LAPTOP-HF study

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

Relypsa commences enrollment for RLY5016 Phase 2 study in heart failure patients with chronic kidney disease

BIOTRONIK announces 10th anniversary of world's first wireless, mobile patient monitoring technology

New public service advertisements to spread preventive medical testing awareness

ARBs may be linked with increased risk of developing cancer: US scientists

BIOTRONIK announces commercial availability of new ProMRI Pacing Systems

Mechanical heart pumps can improve survival among patients with life-threatening heart failure: Thesis

FDA grants HeartWare approval for IDE destination therapy study of Ventricular Assist System

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News